CGON earnings: next report 2026-08-07, real EPS beat/miss history, analyst consensus Buy, P/E -29.62. Updated 2026-07-23.
CG Oncology (CGON) Research Hub
CG Oncology (CGON) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 72.35 USD (+0.54%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -29.62, market cap 6.21B. This hub links to the full technical, earnings and options research available for CGON.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 72.35 USD (+0.54%) |
| 52-week range | 59.14 USD – 80.97 USD |
| Trend regime | Range |
| 14-day RSI | 44 (Bearish) |
| Trailing P/E | -29.62 |
| Market cap | 6.21B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-07 |
Available research for CGON
Covered Call on CGON: how it works, illustrative setup around the real 72.35 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on CGON: how it works, illustrative setup around the real 72.35 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on CGON: how it works, illustrative setup around the real 72.35 USD price, max profit/loss, breakeven and when to use it. Educational.
CGON technical analysis: range, last 72.35 USD, RSI 44, 52w range 59.14 USD–80.97 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is CGON in?
CG Oncology (CGON) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is CGON in an uptrend or downtrend?
As of 2026-09-11, CGON is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is CGON's trailing P/E ratio?
CGON's trailing P/E is -29.62, with a market cap of 6.21B. See the earnings research page for full valuation detail.
When does CGON next report earnings?
CGON is next scheduled to report earnings on 2026-08-07, with a consensus EPS estimate of -0.7 USD.